Thursday, July 14, 2011

Bristol-Myers Squibb returns another cancer drug to Exelixis

Bristol-Myers Squibb is returning rights to an experimental cancer drug to Exelixis Inc. — the second time it has sent a drug back to the South San Francisco biotech company in little more than a year.

No comments:

Post a Comment